Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
Authors:
- S M AquiloniusSAS M Aquilonius
- S A EckernasSES A Eckernas
- P HartvigPHP Hartvig
- B LindstromBLB Lindstrom
- P O OstermanPOP O Osterman
- E StalbergESE Stalberg
Open Access
- 1 October 1983
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 46 (10) , 929-935
Abstract
Determination of plasma concentration of pyridostigmine in 20 myasthenic patients on maintenance therapy revealed rather small intraindividual variations within a dose interval. The predose concentration varied considerably between different patients and up to seven fold in patients on the same daily dose. No pharmacokinetic interaction between pyridostigmine and neostigmine was found in five patients studied. In six patients the decrement in the deltoid muscle was studied in parallel with determination of the plasma concentrations following administration of pyridostigmine or neostigmine. In these patients the existence of a "bell-shaped" dose response curve is suggested with the maximal effect at a concentration of 30-60 ng/ml for pyridostigmine and 5-15 ng/ml for neostigmine.Keywords
This publication has 17 references indexed in Scilit:
- The relationship of plasma levels of pyridostigmine to clinical effect in patients with myasthenia gravisJournal of Neurology, Neurosurgery & Psychiatry, 1981
- Plasma pyridostigmine levels in myasthenia gravisNeurology, 1981
- Pharmacokinetics and oral bioavailability of pyridostigmine in manEuropean Journal of Clinical Pharmacology, 1980
- ESTRIP, a BASIC Computer Program for Obtaining Initial Polyexponential Parameter EstimatesJournal of Pharmaceutical Sciences, 1978
- Renal Clearance of Pyridostigmine in Patients with Myasthenia gravisEuropean Neurology, 1977
- The pharmacokinetics of pyridostigmineNeurology, 1976
- A quantitative gas-liquid chromatographic method for the determination of neostigmine and pyridostigmine in human plasmaJournal of Chromatography A, 1976
- SINGLE‐MUSCLE‐FIBER RECORDING OF THE JITTER PHENOMENON IN PATIENTS WITH MYASTHENIA GRAVIS AND IN MEMBERS OF THEIR FAMILIES*Annals of the New York Academy of Sciences, 1976
- Metabolism of 14 C‐labeled pyridostigmine in myasthenia gravisNeurology, 1970
- Studies in myasthenia gravisJournal of the Neurological Sciences, 1964